SurvivorNet on MSN
Colon cancer is not one disease: Why BRAF & KRAS mutations matter
Today, doctors are increasingly looking at the genetic makeup of each patient’s tumor to guide treatment decisions.
Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...
SurvivorNet on MSN
'Very promising': New cancer drug, Plixorafenib, shows promise for hard‑to‑treat brain tumors as FDA speeds its development
The U.S. Food and Drug Administration (FDA) has granted plixorafenib a Breakthrough Therapy Designation, signaling ...
@mooner As a heads up on the genetic testing, I suggest bringing (or better yet also uploading to MyChart) the contact information for the pathologist who identified ameloblastoma. MDA was able to get ...
The FDA granted breakthrough therapy designation to plixorafenib for adult patients with BRAF V600E–mutated high-grade glioma ...
Mixed histiocytosis (Langerhans cell histiocytosis [LCH] / Erdheim-Chester disease [ECD]) developing after treatment for ...
BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...
Mixed histiocytosis (Langerhans cell histiocytosis [LCH] / Erdheim-Chester disease [ECD]) developing after treatment for initial skull LCH is not well ...
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial Using AI, we identified publications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results